Austin, Texas Law Firm

Pancreatic Cancer Health Risk: Persons Taking Diabetes Drugs Should Be Aware of a Potential Increased Pancreatic Cancer Health Risk That May Be Caused By Incretin Class Diabetic Drugs by Defective Drug Pancreatic Cancer Lawyer Jason S. Coomer 

Recent scientific studies have shown that several diabetes drugs may cause an increased risk of pancreatic cancer.  Persons taking Januvia, Janument, Victoza, Byetta, Onglyza, Tradjenta, Bydureon, Oseni, and other diabetes drugs should be aware of the potential dangers.  If you have been taking a diabetes drug and have been diagnosed with Pancreatic Cancer or you have lost a loved one that was taking a diabetes drug and was diagnosed with pancreatic cancer, please report the adverse action to the prescribing medical doctor and FDA as soon as possible.  

For persons that have been diagnosed with pancreatic cancer or families that have a loved one that has been diagnosed with pancreatic cancer or have lost a loved one from pancreatic cancer, please feel free to send an e-mail message to Pancreatic Cancer Lawyer Jason Coomer or use our online form  for a free case evaluation.

Diabetes Drugs in the Incretin Mimetic Class May Cause An Increased Risk of Pancreatic Cancer

Diabetes drugs in the incretin mimetic class may cause an increased health risk of pancreatic cancer and pancreatitis.  These incretin diabetes drug include exenatide (Byetta, Bydureon), liraglutide (Victoza), sitagliptin (Januvia, Janumet, Janumet XR, Juvisync), saxagliptin (Onglyza, Kombiglyze XR), alogliptin (Nesina, Kazano, Oseni), and linagliptin (Tradjenta, Jentadueto). These drugs work by mimicking the incretin hormones that the body usually produces naturally to stimulate the release of insulin in response to a meal. They are used along with diet and exercise to lower blood sugar in adults with type 2 diabetes.  Many of these incretin diabetes drugs already include a black box warning regarding thyroid cancer risk, but evidence is growing that these drugs may also create an increased risk of pancreatic cancer.
 
People that are taking incretin diabetes drugs including: Januvia, Janument, Victoza, Byetta, Onglyza, Tradjenta,  Oseni, and other diabetes drugs should be aware of the cancer health risks. If you have been taking a diabetes drug and have been diagnosed with Pancreatic Cancer or you have lost a loved one that was taking a diabetes drug and was diagnosed with pancreatic cancer, please report the adverse action to the prescribing medical doctor and FDA as soon as possible.

Pancreatic Cancer Including Pancreatic Adenocarcinoma and other Forms of Exocrine Pancreas Cancers Are Difficult to Diagnose and Are Often Not Diagnosed Until Late in the Course of the Disease

Pancreatic cancer is the fourth leading cause of cancer death for both men and women and is one of the most deadly of all types of cancer. This year approximately 45,000 Americans will be diagnosed with pancreatic cancer and about 38,000 will die from it.  One of the reasons that pancreatic cancer is so deadly is that it it difficult to diagnose and the diagnosis is often made late in the course of the disease.  Early detection of pancreatic cancer is essential and will greatly improve a person's chances of surviving the disease. As such, people that have taken diabetes drugs, especially those with symptoms of weight loss, dark urine and clay-colored stools, back pain, and jaundice, should seek advice from a qualified medical professional as to if they may have pancreatic cancer and what symptoms they should be aware of to detect any early onset of pancreatic cancer.

The Most Common Type of Pancreatic Cancer is Pancreatic Adenocarcinoma Which Includes About 90% of Cases of Pancreatic Cancer: Pancreactic Adenocarcinoma is a Form of Exocrine Pancreas Cancer

The most common kind of pancreatic cancer is pancreatic adenocarcinoma and includes about 90% of the cases of pancreatic cancer.  Pancreatic adenocarcinoma is a cancerous overgrowth of exocrine pancreatic cells and is unfortunately commonly undetected until it is too late for the patient.  Pancreatic adenocarcinoma because of late detection can often result a fatal diagnosis with very limited survival time. Other forms of exocrine pancreas cancer include: intraductal papillary mucinous neoplasm (IPMN), adenosquamous carcinomas, acinar cell carcinomas, mucinous cystadenocarcinomas, signet ring cell carcinomas, hepatoid carcinomas, colloid carcinomas, undifferentiated carcinomas, pancreatoblastomas, and undifferentiated carcinomas with osteoclast-like giant cells.

Pancreatic Cancer Detection: Understanding and Identifying Symptoms of Pancreatic Cancer Can Be Important In Early Detection and Treatment of Pancreatic Cancer Resulting in Higher Pancreatic Cancer Survival Rates

Symptoms of pancreatic cancer can include: dark urine and clay-colored stools, fatigue and weakness, jaundice (a yellow color in the skin, mucus membranes, or eyes), loss of appetite and weight loss, nausea and vomiting, pain or discomfort in the upper part of the belly or abdomen, back pain, blood clots, diarrhea, and indigestion.

Pancreatic cancer is often not detected early on and is often advanced when it is first found.  As such, ninety-five percent of the people diagnosed with this cancer will not be alive 5 years later.  Some patients have pancreatic cancer that can be surgically removed are cured. However, in more than 80% of patients the tumor has already spread and cannot be completely removed at the time of diagnosis.  In the few cases where pancreatic tumors can be removed by surgery. The standard surgical procedure to remove pancreatic tumors is called a Whipple procedure (pancreatoduodenectomy or pancreaticoduodenectomy). This surgery should be done by an experienced surgeon and at a medical center that performs the procedure often. Some studies suggest that the Whipple procedure is best performed at hospitals that do more than five of these surgeries per year.

When the tumor has not spread out of the pancreas, but cannot be removed, radiation therapy and chemotherapy together may be recommended. When the tumor has spread (metastasized) to other organs such as the liver, chemotherapy alone is usually used. The standard chemotherapy drug is gemcitabine, but other drugs may be used. Gemcitabine can help about 25% of patients.

Patients whose tumor cannot be totally removed, but who have a blockage of the tubes that transport bile (biliary obstruction) must have that blockage relieved. There are two approaches including surgery and placement of a tiny metal tube (biliary stent) during ERCP.

Managing pain and other symptoms is an important part of treating advanced pancreatic cancer. Palliative care tams and hospice can help with pain and symptom management, and provide psychological support for patients and their families during the illness.

The Diabetes Drug Market is Over $40 Billion Each Year and Growing Rapidly Encouraging Drug Companies To Push Dangerous Diabetes Drugs For Profits

More than 300 million people worldwide suffer from diabetes, including about 30 million Americans.  In 2010, the global prevalence of diabetes was estimated to have reached 285 million and predicted to reach 438 million by 2030. The corresponding figures for North America were 37.4 million in 2010 and 53.2 million by 2030 and in Europe 55.2 million in 2010 and 66.2 million in 2030.  The global market for products in the management of diabetes currently stands at $41 billion and is on pace to grow to over $114 billion by 2018.

The Diabetes Drugs Januvia and Janumet May Cause An Increased Risk of Pancreatic Cancer by Texas Januvia and Janument Panceatic Cancer Lawyer Jason S. Coomer

The diabetes drugs, Januvia and Janumet, may cause an increased risk of pancreatic cancer in patients using JanuviaIf you have lost a loved one from Pancreatic Cancer, please report the adverse action to the prescribing medical doctor as soon as possible.  As an Januvia Cancer Death Lawyer, Jason S. Coomer, helps families that have lost a family member from cancer including pancreatic cancer.  For more information on this topic, please go to the following web page on Januvia Pancreatic Cancer Lawsuits and Janumet Pancreatic Cancer Lawsuits.

The Diabetes Drug Byetta May Cause An Increased Risk of Pancreatic Cancer by Texas Byetta Pancreatic Cancer Lawyer Jason S. Coomer

The injectable diabetes drug, Byetta, may cause an increased risk of pancreatic cancer in patientsIf you have lost a loved one from Pancreatic Cancer, please report the adverse action to the prescribing medical doctor as soon as possible.  As a Byetta Pancreatic Cancer Lawyer, Jason S. Coomer, helps people that have suffered from defective drugs and families that have lost a family member from cancer including pancreatic cancer.  For more information on this topic, please go to the following web page on Byetta Pancreatic Cancer Lawsuits and Exenatide Pancreatic Cancer Lawsuits.

The Diabetes Drug Victoza May Cause An Increased Risk of Pancreatic Cancer by Texas Victoza Pancreatic Cancer Lawyer Jason Coomer

The consumer group, Public Citizen, has filed a petition with the Food and Drug Administration (FDA) requesting that the agency immediately remove the diabetes drug, Victoza, from the market the increasingly prescribed diabetes drug Victoza (liraglutide [rDNA origin] injection) because it puts patients at higher risk of thyroid cancer, pancreatitis, serious allergic reactions and kidney failure that outweigh any documented clinical benefits.  Public Citizen claims that the diabetes drug, Victoza, has a number of possible side effects including pancreatic cancer. This side effect is extremely dangerous, because once a person has pancreatic cancer and that cancer spreads, a patient stands just a 1.8% chance of surviving for longer than five years.

If you have lost a loved one from Pancreatic Cancer or have suffered acute pancreatitis, hemorrhagic pancreatitis, accute necrotizing pancreatitis, or pancreas cancer; and have been using Victoza or another diabetes drug, please report the adverse action to the prescribing medical doctor as soon as possible.  For more Victoza Pancreatic Cancer Lawsuit, Victoza Cancer Death Lawsuit, or Diabetes Drug Pancreas Cancer Lawsuit information, please feel free to contact Victoza Pancreatic Cancer Lawyer, Victoza Diabetes Drug Cancer Lawyer, and Victoza Pancreas Cancer Death Lawyer Jason Coomer a Texas lawyer, or use our online submission form.

For more information on this topic, please go to the following web page on Victoza Pancreatic Cancer Lawsuits and Victoza Cancer Death Lawsuits.

Pancreatic Cancer Lawyers, Texas Pancreatic Cancer Lawyers, Diabetes Drug Pancreatic Adenocarcinoma Lawyers, Diabetes Drug Fatal Cancer Lawyers, and Diabetes Drug Cancer Lawyers

Texas Dangerous Drug Attorney Jason Coomer commonly works with other lawyers throughout Texas, the United States, and the World including Houston Pancreatic Cancer Lawyers, San Antonio Pancreatic Cancer Lawyers, Dallas Pancreatic Cancer Lawyers, New York Diabetes Drug Pancreatic Cancer Lawyers, Chicago Diabetes Drug Pancreatic Cancer Lawyers, and other Texas Pancreatic Cancer Death Lawyers.  By sharing information and working together, his law firm and other firms throughout World are able to provide better representation for their clients.  

If you have lost a loved one from Pancreatic Cancer or have suffered acute pancreatitis, hemorrhagic pancreatitis, accute necrotizing pancreatitis, or pancreas cancer; and have been using a diabetes drug, please report the adverse action to the prescribing medical doctor as soon as possible.  For more information on this topic, please feel free to contact Pancreatic Cancer Lawyer, Pancreatic Adenocarcinoma Lawyer, and Pancreas Cancer Lawyer Jason Coomer a Texas lawyer, or use our online submission form.

FDA Information on Sitagliptin (marketed as Januvia and Janumet)

[09-25-2009] FDA is revising the prescribing information for Januvia (sitagliptin) and Janumet (sitagliptin/metformin) to include information on reported cases of acute pancreatitis in patients using these products.

Sitagliptin, the first in a new class of diabetic drugs called dipeptidyl peptidase-4 (DPP-4) inhibitors, is approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Eighty-eight post-marketing cases of acute pancreatitis, including two cases of hemorrhagic or necrotizing pancreatitis in patients using sitagliptin, were reported to the Agency between October 16, 2006 and February 9, 2009. Based on these reports, FDA is working with the manufacturer of sitagliptin and sitagliptin/metformin to revise the prescribing information to include:

Information regarding post-marketing reports of acute pancreatitis, including the severe forms, hemorrhagic or necrotizing pancreatitis. Recommending that healthcare professionals monitor patients carefully for the development of pancreatitis after initiation or dose increases of sitagliptin or sitagliptin/metformin, and to discontinue sitagliptin or sitagliptin/metformin if pancreatitis is suspected while using these products. Information noting that sitagliptin has not been studied in patients with a history of pancreatitis. Therefore, it is not known whether these patients are at an increased risk for developing pancreatitis while using sitagliptin or sitagliptin/metformin. Sitagliptin or sitagliptin/metformin should be used with caution and with appropriate monitoring in patients with a history of pancreatitis.

Januvia Pancreatic Cancer Lawsuit Information, Januvia Pancreatitis Lawsuit Information and Januvia Pancreas Cancer Lawsuit Information

Between October 16, 2006 and February 9, 2009, the FDA received 88 post-marketing cases of acute pancreatitis, of which 66 required hospitalization. The FDA review also found that in over half of these cases, the patient?s pancreatitis resolved once Januvia was discontinued. While diabetics are more vulnerable to developing pancreatitis than those without the disease, it does appear that taking Januvia can potentially increase that risk. And, if pancreatitis becomes chronic, the inflammation of the pancreas will alter its normal structure and functions.

Pancreatic Cancer, Exocrine Pancreas Cancers (Pancreatic Adenocarcinoma) and Endocrine Pancreatic Cancers

The pancreas is a large organ located behind the stomach and in front of the spine above the level of the belly button. The pancreas performs two main functions:  1) it makes insulin, a hormone that regulates blood sugar levels, and 2) it makes enzymes. The pancreas makes and releases enzymes into the intestines that help the body absorb foods, especially fats.  The pancreas is made of Exocrine cells and Endocrine cells.  Exocrine cells are cells that produce a pancreatic juice that includes enzymes which aid in the digestion of food in the small intestine, breaking up proteins, carbohydrates, and fats. 

The most common kind of pancreatic cancer is pancreatic adenocarcinoma and includes about 90% of the cases of pancreatic cancer.  Pancreatic adenocarcinoma is a cancerous overgrowth of exocrine pancreatic cells and is unfortunately commonly undetected until it is too late for the patient.  Pancreatic adenocarcinoma because of late detection can often result a fatal diagnosis with very limited survival time. Other forms of exocrine pancreas cancer include: intraductal papillary mucinous neoplasm (IPMN), adenosquamous carcinomas, acinar cell carcinomas, mucinous cystadenocarcinomas, signet ring cell carcinomas, hepatoid carcinomas, colloid carcinomas, undifferentiated carcinomas, pancreatoblastomas, and undifferentiated carcinomas with osteoclast-like giant cells.

Endocrine cells are clustered in small groups (called the Islets of Langerhans) scattered throughout the pancreas. These endocrine cells produce important hormones such as insulin, glucagon, and somatostatin.  The hormones called insulin and glucagon help your body control blood sugar levels. Tumors can also occur in these cells, but they are called islet cell tumors and are rare.

The exact cause of pancreatic cancer is unknown. However, it is more common in people with diabetes and people with long-term inflammation of the pancreas (chronic pancreatitis).  It is also thought that the use of Byetta can cause pancreatitis resulting in pancreatic cancer.

Symptoms of pancreatic cancer can include: dark urine and clay-colored stools, fatigue and weakness, jaundice (a yellow color in the skin, mucus membranes, or eyes), loss of appetite and weight loss, nausea and vomiting, pain or discomfort in the upper part of the belly or abdomen, back pain, blood clots, diarrhea, and indigestion.

Pancreatic cancer is often not detected early on and is often advanced when it is first found.  As such, ninety-five percent of the people diagnosed with this cancer will not be alive 5 years later.  Some patients have pancreatic cancer that can be surgically removed are cured. However, in more than 80% of patients the tumor has already spread and cannot be completely removed at the time of diagnosis.  In the few cases where pancreatic tumors can be removed by surgery. The standard surgical procedure to remove pancreatic tumors is called a Whipple procedure (pancreatoduodenectomy or pancreaticoduodenectomy). This surgery should be done by an experienced surgeon and at a medical center that performs the procedure often. Some studies suggest that the Whipple procedure is best performed at hospitals that do more than five of these surgeries per year.

When the tumor has not spread out of the pancreas, but cannot be removed, radiation therapy and chemotherapy together may be recommended. When the tumor has spread (metastasized) to other organs such as the liver, chemotherapy alone is usually used. The standard chemotherapy drug is gemcitabine, but other drugs may be used. Gemcitabine can help about 25% of patients.

Patients whose tumor cannot be totally removed, but who have a blockage of the tubes that transport bile (biliary obstruction) must have that blockage relieved. There are two approaches including surgery and placement of a tiny metal tube (biliary stent) during ERCP.

Managing pain and other symptoms is an important part of treating advanced pancreatic cancer. Palliative care tams and hospice can help with pain and symptom management, and provide psychological support for patients and their families during the illness.

Acute Pancreatitis, Hemorrhagic Pancreatitis, Necrotizing Pancreatitis

Acute pancreatitis is a sudden inflammation of the pancreas that occurs over a short period of time. The pancreas is a digestive organ behind the stomach that secretes essential enzymes needed for the digestion of certain foods, including fats, carbohydrates and proteins. During an episode of acute hemorrhagic pancreatitis, several symptoms relating to digestion and abdomen may occur.  In severe cases, the person may experience confusion, difficulty breathing, or respiratory failure.  The person may also fall into a coma.

The severity of acute pancreatitis may range from mild abdominal discomfort to a severe, life-threatening illness. However, the majority of people with acute pancreatitis (more than 80%) recover completely after receiving the appropriate treatment.  In very severe cases, acute pancreatitis can result in bleeding into the gland, serious tissue damage, infection, and cyst formation. Severe pancreatitis can also create conditions which can harm other vital organs such as the heart, lungs, and kidneys.

The warning signs of pancreatitis include: 1) Upper abdominal pain that radiates into the back. Patients may describe this as a "boring sensation" that may be aggravated by eating, especially foods high in fat. 2) Swollen and tender abdomen 3) Nausea and vomiting 4) Fever  and 5) Increased heart rate.

Acute hemorrhagic pancreatitis is the sudden inflammation of the pancreas. This leads to death of pancreatic tissue and the formation of lesions, causing extensive bleeding.

Necrotizing pancreatitis is a serious health condition where a person's pancreas is inflamed and bleeding. In Necrotizing Pancreatitis patients, there is inflammation and tissue death, with the pancreas destroying itself.  Whereas in Hemorrhagic Pancreatitis patients, the pancreas is bleeding.  Both are serious conditions and should be treated immediately.

Januvia Pancreatic Cancer Death Lawyer, Janumet Pancreatic Cancer Lawyer, Sitagliptin Pancreatic Cancer Lawyer, Sitagliptin/Metformin Pancreatic Cancer Lawyer, Janumet Pancreas Cancer Lawyer, Sitagliptin Panreas Cancer Lawyer, and Januvia Pancreatitis Lawyer

 If you have lost a loved one from Pancreatic Cancer or have suffered acute pancreatitis, hemorrhagic pancreatitis, accute necrotizing pancreatitis, or pancreas cancer; and have been using Januvia, please report the adverse action to the prescribing medical doctor as soon as possible.  For more Januvia Pancreatic Cancer Lawsuit, Januvia Cancer Death Lawsuit, or Januvia Pancreas Cancer Lawsuit information, please feel free to contact Januvia Pancreatic Cancer Lawyer, Januvia Cancer Lawyer, and Januvia Pancreas Cancer Death Lawyer Jason Coomer a Texas lawyer, or use our online submission form.

Licensed by the State Bar of Texas